Description

[R*,S*-(E)]-(±)-7-[3-(4-Fluorophenyl)-5-Hydroxy-1-(1-Methylethyl)-1H-Indol-2-Yl]-3,5-Dihydroxy-6-Heptenoic Acid Monosodium Salt is a high-purity, non-racemic synthetic intermediate of significant pharmaceutical importance. Its value lies in its role as a key chiral building block for the synthesis of complex bioactive molecules, particularly in advanced drug discovery and development programs. This compound is essential for research and manufacturing organizations in the pharmaceutical and biotechnology sectors, where precise stereochemistry and high chemical purity are critical for producing active pharmaceutical ingredients (APIs) and novel therapeutic candidates.

Application

• Pharmaceutical Intermediate: A critical chiral precursor in the multi-step synthesis of proprietary drug candidates and complex APIs.
• Drug Discovery Research: Used in medicinal chemistry for structure-activity relationship (SAR) studies and the development of new molecular entities targeting specific biological pathways.
• Process Chemistry Development: Serves as a standard or starting material for optimizing scalable synthetic routes in process R&D laboratories.
• Reference Standard: Employed as an analytical reference standard for quality control and method validation in pharmaceutical analysis.
• Biochemical Research: Potential use as a tool compound in biochemical assays to study enzyme inhibition or receptor-ligand interactions.
• Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for the cGMP production of clinical trial materials.

Basic Information

Product Name	[R*,S*-(E)]-(±)-7-[3-(4-Fluorophenyl)-5-Hydroxy-1-(1-Methylethyl)-1H-Indol-2-Yl]-3,5-Dihydroxy-6-Heptenoic Acid Monosodium Salt
CAS No.	150767-71-8
Molecular Formula	C25H27FNO6•Na
Molecular Weight	479.48 g/mol
Synonyms	7-[3-(4-Fluorophenyl)-5-hydroxy-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid monosodium salt; (E)-7-[3-(4-Fluorophenyl)-5-hydroxy-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid sodium salt; Sodium (E)-7-[3-(4-fluorophenyl)-5-hydroxy-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoate; Fluorophenyl hydroxy indole heptenoic acid sodium salt; ATR-101 intermediate; Steroidogenic inhibitor intermediate.
EINECS	Contact for details

Quality Control

Our [R*,S*-(E)]-(±)-7-[3-(4-Fluorophenyl)-5-Hydroxy-1-(1-Methylethyl)-1H-Indol-2-Yl]-3,5-Dihydroxy-6-Heptenoic Acid Monosodium Salt is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including chiral HPLC, NMR, and mass spectrometry, to ensure identity, purity, and consistency. We provide comprehensive Certificates of Analysis (COA) with detailed specifications for all critical parameters. Our quality commitment supports applications requiring material for GMP and non-GMP pharmaceutical development.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and light-sensitive; therefore, containers must be kept tightly sealed in a dry environment and protected from light exposure to maintain stability and purity. For long-term storage, consider desiccants and inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0% ee
Water Content (KF)	≤ 2.0%
Residue on Ignition	≤ 0.5%
Heavy Metals	≤ 20 ppm
Related Substances (HPLC)	Total impurities ≤ 2.0%; Any single impurity ≤ 1.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.